NCT01118351View on ClinicalTrials.gov

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

July 31, 2012

Study Completion Date

September 30, 2015

Conditions
Recurrent Bladder CancerTransitional Cell Carcinoma of the Bladder
Interventions
DRUG

sunitinib malate

Given orally

OTHER

immunohistochemistry staining method

Correlative studies

OTHER

TdT-mediated dUTP nick end labeling assay

Correlative studies

OTHER

light microscopy

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

44111

CCF-Fairview Hospital, Cleveland

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Case Comprehensive Cancer Center

OTHER